Beam Therapeutics shares retreat after updated trial data disappoints
Beam Therapeutics shares fell 9% to $26.88 after the company shared updated trial data for BEAM-302 in alpha-1 antitrypsin deficiency.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.